Celcuity公司将于2026年6月2日召开电话会议,讨论Gedatolisib方案针对HR+/HER-晚期乳腺癌的3期Viktoria-1临床试验中PIK3CA突变队列的结果

美股速递
Jun 01

Celcuity公司计划于2026年6月2日举行一场电话会议,专门探讨其关键候选药物Gedatolisib联合方案在HR+/HER-晚期乳腺癌患者中的最新临床数据。此次会议的核心议题,将聚焦于3期Viktoria-1临床试验中,针对携带PIK3CA基因突变的患者队列所获得的详细结果。该数据的公布,预计将为评估Gedatolisib在这一特定患者群体中的疗效与安全性提供关键洞见,并可能影响未来的治疗策略与监管路径。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10